Equity Overview
Price & Market Data
Price: $0.868
Daily Change: $0.00 / 0.00%
Daily Range: $0.55 - $0.96
Market Cap: $77,559,072
Daily Volume: 4,862,648
Performance Metrics
1 Week: -19.63%
1 Month: -18.11%
3 Months: -35.70%
6 Months: -42.52%
1 Year: 110.2%
YTD: -35.70%
Company Details
Employees: 14
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.